Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Bumps Forecast On 'Significant Momentum' Pre-Shire

Executive Summary

Takeda raises full-year forecast after "significant momentum" in the first half, driven by mainstays, cost savings and delayed US generic competition to Velcade.

You may also be interested in...



Multiple Myeloma: Pricing And Reimbursement Challenges Escalate Even As Blockbusters Go Generic

As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.

Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data

Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.

Shire Continues To Grow HAE Franchise With Takhzyro, As Hemophilia Takes A Hit

Approved in late August, the HAE prophylaxis drug has already yielded $51m in US revenues, with EU approval expected by year-end. The HAE franchise is a growth leader for Shire, despite peaks and valleys due to supply issues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel